• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Mumbai, Sept. 11 Sun Pharmaceutical Industries Ltd is evaluating the launch options for its generic version of heart-burn medicine pantoprazole in the US market. The Mumbai-based drug company said this following the final approval it received from the US Food and Drug Administration (USFDA) to sell generic copies of Wyeth’s Protonix (pantoprazole) tablets. The generic pantoprazole tablets are equivalents of Wyeth’s Protonix ® delayed release tablets in two strengths: 20 mg (base) and 40 mg (base), a note from the company said. These strengths of Protonix have annual sales of approximately $2.3 billion in the US. Since it was among the first to file an application to sell generic pantoprazole in the US, Sun Pharma would also have 180 days of exclusive sales in the market, the company said.

— Our Bureau

More Stories on : Regulatory Bodies & Rulings | Sun Pharmaceutical Industries Ltd | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Renault-Nissan’s R&D centre to work on cars for global markets

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line